ClinicalTrials.gg
RecruitingNCT07772024DOMMINO-2Updated Aug 19, 2026

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of InoPd and Investigator's choice of SAT in Multiple Myeloma Refractory and Multiple Myeloma in Relapse, sponsored by CellCentric Ltd.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by CellCentric Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.

Planned enrollment
93rd of 1,901
450 · median 36
Started
2026
with 75 others
Phase 3
184 of 2,168
28 open now
Primary completion
2029-11
later than 417 of 499 live
Registered
2,162nd of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 93rd largest by planned enrollment of the 1,901 interventional ones that give a count, is one of 76 that started in 2026, is one of 184 in phase 3, reaches primary completion later than 417 of the 499 other live ones, and was the 2,162nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

269 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to find out whether inobrodib, when given with pomalidomide and dexamethasone, works better than standard treatment for people whose multiple myeloma has come back or has not improved after previous treatment. The study will look at how long people taking part in the study ("Participants") live without their myeloma getting worse, and how many people's myeloma improves (responds) following treatment.

The study will also look at how long participants live overall, how quickly treatment works, how long the response lasts, whether very small amounts of myeloma can still be found after a good response, quality of life, side effects, and the amount of inobrodib in the blood.

Participants receive treatment in 28-day cycles. One group receives inobrodib by mouth twice a day for 4 days, followed by 3 days without inobrodib each week; pomalidomide by mouth once a day on Days 1 to 21 of each cycle; and dexamethasone once each week.

The other group receives 1 standard treatment chosen by the study doctor from the following treatment options: daratumumab, pomalidomide, and dexamethasone; elotuzumab, pomalidomide, and dexamethasone; or carfilzomib and dexamethasone. Some standard treatments are given by injection or infusion at the study site. Other medicines, such as tablets or capsules, may be taken by mouth as instructed by the study team.

Study checks include questions about symptoms and side effects, review of other medicines, physical checks, blood pressure and other vital sign checks, heart tracing tests, blood and urine tests, scans where needed, bone marrow samples, and questionnaires about symptoms and daily life. Participants in the inobrodib group will have extra blood samples to measure the amount of inobrodib in the blood. Some participants may also have extra research blood samples at selected visits.

Read the detailed description

This is a Phase 3, multicenter, open-label, randomized study to evaluate inobrodib in combination with pomalidomide and dexamethasone (InoPd) versus standard available therapy (SAT), defined as Investigator's choice of daratumumab or elotuzumab in combination with pomalidomide and dexamethasone (DPd and EPd, respectively) or carfilzomib in combination with dexamethasone (Kd), in participants with relapsed or refractory multiple myeloma (RRMM).

Participants must be 18 years or older and have received 1 to 4 prior lines of therapy only.

Approximately 450 participants will be randomized 1:1 to be treated with either InoPd (Arm A) or Investigator's choice of SAT (Arm B), which includes DPd, EPd and Kd.

Study treatment should be continued until disease progression, initiation of new anticancer therapy, unacceptable toxicity or the participant meets any criteria for withdrawal from the study.

The dual primary objectives are to compare the efficacy of InoPd with Investigator's choice of SAT in terms of progression-free survival (PFS) and objective response rate (ORR) by Blinded Independent Central Review (BICR) in participants receiving InoPd versus participants receiving SAT.

The study will use a Steering Committee, consisting of selected participating Principal Investigators, Contract Research Organization (CRO) and Sponsor representatives, and an Independent Data Monitoring Committee (IDMC), for the purposes of conduct and oversight of the study.

03

Conditions studied

  • Multiple Myeloma Refractory
  • Multiple Myeloma in Relapse

Browse trials for

Keywords

  • Inobrodib
  • Pomalidomide
  • Pomalyst
  • Imnovid
  • Dexamethasone
  • p300-CBP Transcription Factors
  • CCS1477
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older (or the minimum age of consent under local rules, if that is 18 or over)
  • A diagnosis of multiple myeloma that has either come back () or did not respond (refractory) after the most recent treatment
  • Myeloma that can be measured using standard study tests (blood and/or urine tests)
  • Between 1 and 4 previous courses (lines) of myeloma treatment, which must have included both a treatment that targets CD38 (such as daratumumab or isatuximab) and lenalidomide
  • Well enough to carry out daily activities with little or no help ( [ECOG] performance status of 0 to 2)
  • Suitable blood test results and adequate kidney and liver function
  • Willingness to use highly effective measures (if sexually active) with all sexual partners

Exclusion criteria

Exclusion Criteria:

  • Recent anticancer treatment before starting study treatment: any experimental medicine, chemotherapy, immunotherapy or other anticancer treatment within 14 days or 5 half-lives (whichever is shorter), or certain antibody-based treatments within longer set periods
  • Previous treatment with a medicine that works in the same way as inobrodib (a p300/CBP bromodomain inhibitor)
  • Myeloma that has already stopped responding to pomalidomide (pomalidomide-), unless only short-term pomalidomide was used and the study doctor confirms the person still meets the study rules
  • Unable to receive at least one of the standard treatment options offered in the study, or unable/unwilling to follow the requirements for at least one of those options
  • Taking medicines, herbal supplements or foods (for example, strong inducers or inhibitors) that would interfere with the study treatment
  • Major surgery within 4 weeks before the first dose of study treatment
  • A within 4 weeks before study treatment
  • A recent stem cell transplant, or ongoing transplant-related problems such as
  • Myeloma affecting the brain, spinal fluid or spinal cord, or ongoing pressure on the spinal cord
  • Another active cancer (progressing or needing a change in treatment) in the last 24 months, other than multiple myeloma, apart from certain low-risk or fully treated cancers
  • Serious or uncontrolled medical problems, such as uncontrolled heart, lung, liver, bleeding or diabetes conditions, uncontrolled high blood pressure, or a heart-rhythm problem (including )
  • An active or uncontrolled infection, including certain cases of , or
  • Digestive problems that could stop the study medicines being swallowed or properly absorbed
  • Pregnant or breastfeeding, or planning to become pregnant, father a child or donate sperm during treatment or the required post-treatment period
  • Any illness or medical history that could affect safety, the ability to follow study requirements, or the interpretation of study results
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    InoPd

    Inobrodib in combination with pomalidomide and dexamethasone

    Drug: InoPd

  • Active comparator
    Investigator's choice of Standard Available Therapy

    Investigator's choice of elotuzumab in combination with pomalidomide and dexamethasone (EPd), daratumumab in combination with pomalidomide and dexamethasone (DPd), or carfilzomib in combination with dexamethasone (Kd).

    Drug: Investigator's choice of SAT

Interventions

  • DrugInoPd

    Inobrodib in combination with pomalidomide and dexamethasone. Inobrodib 20 mg orally (PO) twice daily (b.i.d.), 4 days on/3 days off. Pomalidomide 4 mg PO once daily (o.d.) on Days 1 to 21 of each 28-day cycle. Dexamethasone 40 mg PO every week (q1w) (20 mg if \>75 years old) on Days 1, 8, 15 and 22 of each 28-day cycle. Treatment will continue until progressive disease, death, unacceptable side effects, withdrawal of consent or end of study, whichever occurs first.

    Also known as: Inobrodib, CCS1477, Pomalidomide, Pomalyst, Imnovid, Dexamethasone

  • Investigator's choice of elotuzumab in combination with pomalidomide and dexamethasone (EPd), daratumumab in combination with pomalidomide and dexamethasone (DPd), or carfilzomib in combination with dexamethasone (Kd). Treatment will continue until progressive disease, death, unacceptable side effects, withdrawal of consent or end of study, whichever occurs first.

    Also known as: Elotuzumab, Empliciti, Daratumumab, Darzalex, Darzalex Faspro, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Imnovid, Dexamethasone

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) assessed by Blinded Independent Central Review (BICR)

    Defined as the time from randomization until the earliest date of PD based on International Myeloma Working Group (IMWG) criteria assessed by BICR, or death due to any cause

    Time frame: From randomization until progressive disease or death, assessed every 28 days and followed until the final PFS analysis after approximately 330 PFS events; estimated up to approximately 38 months after the start of enrollment

  2. Objective Response Rate (ORR) assessed by BICR

    Defined as the percentage of participants with a confirmed PR or better, based on IMWG criteria assessed by BICR

    Time frame: From randomization until confirmed progressive disease, initiation of subsequent anticancer therapy, death, withdrawal, or the ORR data cutoff, whichever occurs first; disease response assessed every 28 days (up to 48 months)

Secondary outcomes

  1. Overall Survival (OS)

    Defined as the time from randomization to the date of death due to any cause

    Time frame: From randomization until death from any cause or the final OS analysis after approximately 329 deaths; survival status assessed every 12 weeks after disease progression or treatment discontinuation (up to 48 months)

  2. PFS Assessed by the Investigator

    Defined as the time from randomization to the earliest occurrence of progressive disease, as determined by the Investigator according to IMWG response criteria, or death from any cause.

    Time frame: From randomization until progressive disease or death; disease assessments performed every 28 days until confirmed progression, death, withdrawal, loss to follow-up, or end of study (up to 48 months)

  3. ORR Assessed by the Investigator

    Percentage of participants with a confirmed PR or better as determined by the Investigator according to IMWG response criteria

    Time frame: From randomization until confirmed progressive disease, initiation of subsequent anticancer therapy, death, withdrawal, or end of study; assessed every 28 days (up to 48 months)

  4. Minimal Residual Disease (MRD) Negativity Rate

    Percentage of participants achieving minimal residual disease (MRD) negativity at CR or better, measured by next-generation sequencing

    Time frame: At confirmed CR or better; if MRD negativity is not demonstrated at CR, reassessed within 3 to 6 months after confirmation of CR or better (up to 48 months)

  5. Duration of Response (DoR) Assessed by BICR

    Defined, among participants with a confirmed PR or better, as the time from the first documented response to progressive disease determined by BICR or death from any cause, whichever occurs first

    Time frame: From the first documented confirmed response until progressive disease or death; assessed every 28 days until progression or end of study (up to 48 months)

  6. DoR Assessed by the Investigator

    Defined, among participants with a confirmed PR or better, as the time from the first documented response to progressive disease determined by the Investigator or death from any cause, whichever occurs first

    Time frame: From the first documented confirmed response until progressive disease or death; assessed every 28 days until progression or end of study (up to 48 months)

  7. Time to Response (TTR) Assessed by BICR

    Defined, among participants achieving a confirmed response, as the time from randomization to the first documented PR or better determined by BICR according to IMWG response criteria

    Time frame: From randomization to the first documented confirmed response; assessed every 28 days (up to 48 months)

  8. TTR Assessed by the Investigator

    Defined, among participants achieving a confirmed response, as the time from randomization to the first documented PR or better determined by the Investigator according to IMWG response criteria

    Time frame: From randomization to the first documented confirmed response; assessed every 28 days (up to 48 months)

  9. Very Good Partial Response (VGPR) or Better Rate Assessed by BICR

    Percentage of participants with a confirmed VGPR or better-VGPR, CR, or sCR-as determined by BICR according to IMWG response criteria

    Time frame: From randomization until progressive disease, initiation of subsequent anticancer therapy, death, withdrawal, or end of study; assessed every 28 days (up to 48 months)

  10. VGPR or Better Rate Assessed by the Investigator

    Percentage of participants with a confirmed VGPR or better as determined by the Investigator according to IMWG response criteria

    Time frame: From randomization until progressive disease, initiation of subsequent anticancer therapy, death, withdrawal, or end of study; assessed every 28 days (up to 48 months)

  11. Complete Response (CR) or Better Rate Assessed by BICR

    Percentage of participants with a confirmed CR or sCR as determined by BICR according to IMWG response criteria

    Time frame: From randomization until progressive disease, initiation of subsequent anticancer therapy, death, withdrawal, or end of study; assessed every 28 days (up to 48 months)

  12. CR or Better Rate Assessed by the Investigator

    Percentage of participants with a confirmed CR or sCR as determined by the Investigator according to IMWG response criteria

    Time frame: From randomization until progressive disease, initiation of subsequent anticancer therapy, death, withdrawal, or end of study; assessed every 28 days (up to 48 months)

  13. Change From Baseline in EORTC QLQ-C30 Scores

    Defined as the change from baseline in functional, symptom, and global health status/quality-of-life scores from the EORTC QLQ-C30 questionnaire

    Time frame: Assessed at baseline and protocol-specified visits during the first year, then every 3 months until treatment discontinuation, withdrawal, or the end of study (up to 48 months)

  14. Change From Baseline in EORTC QLQ-MY20 Disease Symptoms Score

    Defined as the change from baseline in the Disease Symptoms domain score of the EORTC QLQ-MY20 questionnaire

    Time frame: Assessed at baseline and protocol-specified visits during the first year, then every 3 months until treatment discontinuation, withdrawal, or the end of study (up to 48 months)

  15. Change From Baseline in EQ-5D-5L Health Status

    Defined as the change from baseline in the EQ-5D-5L health-state index and visual analogue scale scores

    Time frame: Assessed at baseline and protocol-specified visits during the first year, then every 3 months until treatment discontinuation, withdrawal, or the end of study (up to 48 months)

  16. Treatment Side-Effect Bother Assessed by FACT-GP5

    Defined as participants' responses to FACT-GP5 regarding how bothered they were by treatment side effects during the previous 7 days

    Time frame: Assessed at baseline and protocol-specified visits during the first year, then every 3 months until treatment discontinuation, withdrawal, or the end of study (up to 48 months)

  17. Symptomatic Adverse Events Assessed by PRO-CTCAE

    Defined as participant-reported frequency, severity, or interference of selected symptomatic adverse events using the PRO-CTCAE

    Time frame: Assessed at baseline and protocol-specified visits during the first year, then every 3 months until treatment discontinuation, withdrawal, or the end of study (up to 48 months)

  18. Participants With Treatment-Emergent Adverse Events

    Defined as the number and percentage of participants with adverse events that begin or worsen after the first dose of study treatment

    Time frame: Assessed from the first dose of study treatment through 28 days after the last dose (up to 48 months)

  19. Change From Baseline in Electrocardiogram Parameters

    Defined as changes from baseline and clinically significant abnormalities in protocol-specified 12-lead electrocardiogram parameters

    Time frame: Assessed at baseline and protocol-specified visits during treatment through the 28-day post-treatment follow-up visit (up to 48 months)

  20. Change From Baseline in Vital Signs

    Defined as changes from baseline and clinically significant abnormalities in protocol-specified vital-sign measurements

    Time frame: Assessed at baseline and protocol-specified visits during treatment through the 28-day post-treatment follow-up visit (up to 48 months)

  21. Participants With Laboratory Abnormalities

    Defined as the number and percentage of participants with hematology, chemistry, or other protocol-specified laboratory abnormalities

    Time frame: Assessed at baseline and protocol-specified visits during treatment through the 28-day post-treatment follow-up visit (up to 48 months)

  22. Plasma Concentrations of Inobrodib

    Defined as the measured plasma concentrations of inobrodib and, where analyzed, its primary metabolite CCS1532

    Time frame: Assessed at protocol-specified predose and postdose time points during treatment (up to 48 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The final clinical study report will be provided to the Investigators. The Sponsor will publicly disclose study results through posting on ClinicalTrials.gov and any other applicable public registries in accordance with local regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Nov 2029, 39 months later.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 39 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2026
First posted
Aug 19, 2026
StartEst.
Aug 2026
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2031
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07772024
Lead sponsor
CellCentric Ltd.
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Aug 2026 (estimated)
Primary completion
Nov 2029 (estimated)
Completion
Nov 2031 (estimated)
Last update
Aug 19, 2026

Study contacts

CCS1477-05 Clinical Operations
Contact
DOMMINO-2@cellcentric.com
+44 1799 531130
Study Director
study director · CellCentric Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CCS1477

Start the discussion